667 related articles for article (PubMed ID: 1909220)
1. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
[TBL] [Abstract][Full Text] [Related]
2. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
3. Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
Lu HR; Lijnen HR; Stassen JM; Collen D
Blood; 1991 Jul; 78(1):125-31. PubMed ID: 1906351
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase.
Holvoet P; Laroche Y; Stassen JM; Lijnen HR; Van Hoef B; De Cock F; Van Houtven A; Gansemans Y; Matthyssens G; Collen D
Blood; 1993 Feb; 81(3):696-703. PubMed ID: 8427962
[TBL] [Abstract][Full Text] [Related]
5. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
[TBL] [Abstract][Full Text] [Related]
6. Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates.
Holvoet P; Dewerchin M; Stassen JM; Lijnen HR; Tollenaere T; Gaffney PJ; Collen D
Circulation; 1993 Mar; 87(3):1007-16. PubMed ID: 8443877
[TBL] [Abstract][Full Text] [Related]
7. Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons.
Imura Y; Stassen JM; Kurokawa T; Iwasa S; Lijnen HR; Collen D
Blood; 1992 May; 79(9):2322-9. PubMed ID: 1571545
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
Rapold HJ; Wu ZM; Stassen T; Van de Werf F; Collen D
Blood; 1990 Oct; 76(8):1558-63. PubMed ID: 2119830
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
[TBL] [Abstract][Full Text] [Related]
10. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
Collen D; Dewerchin M; Rapold HJ; Lijnen HR; Stassen JM
Circulation; 1990 Nov; 82(5):1744-53. PubMed ID: 2121385
[TBL] [Abstract][Full Text] [Related]
11. Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits.
Spriggs DJ; Stassen JM; Hashimoto Y; Collen D
Blood; 1989 Apr; 73(5):1207-12. PubMed ID: 2495034
[TBL] [Abstract][Full Text] [Related]
12. Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model.
Collen D; Lijnen HR; Vanlinthout I; Kieckens L; Nelles L; Stassen JM
Thromb Haemost; 1991 Feb; 65(2):174-80. PubMed ID: 1905070
[TBL] [Abstract][Full Text] [Related]
13. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.
Badylak SF; Voytik S; Klabunde RE; Henkin J; Leski M
Thromb Res; 1988 Nov; 52(4):295-312. PubMed ID: 3144052
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
Collen D; Stassen JM; De Cock F
Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
[TBL] [Abstract][Full Text] [Related]
15. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
[TBL] [Abstract][Full Text] [Related]
16. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.
Dewerchin M; Lijnen HR; Stassen JM; De Cock F; Quertermous T; Ginsberg MH; Plow EF; Collen D
Blood; 1991 Aug; 78(4):1005-18. PubMed ID: 1831057
[TBL] [Abstract][Full Text] [Related]
17. K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man.
Collen D; Nelles L; De Cock F; Lemmens G; Van Coetsem T; Demarsin E; Lijnen HR
Thromb Res; 1992 Feb; 65(3):421-38. PubMed ID: 1631805
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.
Li XK; Lijnen HR; Nelles L; Van Hoef B; Stassen JM; Collen D
Blood; 1992 Jan; 79(2):417-29. PubMed ID: 1730087
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits.
Collen D; Stassen JM; Larsen G
Blood; 1988 Jan; 71(1):216-9. PubMed ID: 3120823
[TBL] [Abstract][Full Text] [Related]
20. Additive fibrinolysis by recombinant tissue-type plasminogen activator (r-t-PA) and recombinant single-chain urokinase type plasminogen activator (r-scu-PA) in rabbit pulmonary thrombosis.
Schneider J; Friderichs E; Günzler WA; Flohé L
Thromb Res; 1989 Oct; 56(1):59-65. PubMed ID: 2512686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
